This trial is investigating whether trastuzumab deruxtecan, either alone or in combination with anastrozole, is effective in treating patients with HER2 low, hormone receptor positive breast cancer.
1 Primary · 4 Secondary · Reporting Duration: Baseline to surgery
88 Total Participants · 2 Treatment Groups
Primary Treatment: Trastuzumab Deruxtecan · No Placebo Group · Phase 2
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: